Phase I Study of MEK 162 for Children With Progressive or Recurrent Cancer and a Phase II Study for Children With Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Binimetinib (Primary)
- Indications Cancer; Glioma; Tumours
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 21 Apr 2016 Status changed from not yet recruiting to recruiting.
- 09 Nov 2015 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020, as reported by ClinicalTrials.gov.